Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3019% below fair value
$1.14−0.03 (-2.56%)
Close on Nov 16, 2026Market cap $303.43MP/E –Yield –
Autolus Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Autolus Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$238.85M. For fiscal 2025 it was -$262.25M. The highest annual figure on record is -$132.59M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$262.25M | – |
| FY2024 | Dec 31, 2024 | -$233.87M | – |
| FY2023 | Dec 31, 2023 | -$173.14M | – |
| FY2022 | Dec 31, 2022 | -$135.99M | – |
| FY2021 | Dec 31, 2021 | -$132.59M | – |
| FY2020 | Dec 31, 2020 | -$162.49M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$41.68M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$57.30M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$70.32M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$69.54M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$59.13M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$63.25M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$73.95M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$65.94M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$57.03M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$36.95M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$51.50M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$41.53M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$42.87M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$37.25M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$10.00M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$38.21M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$45.67M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$41.24M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$38.28M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$37.30M | – |
See a number that looks wrong?